RUBINSTEIN JULIE sold $929K of ADPT
RUBINSTEIN JULIE (President and COO) sold 35,643 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $26.06 ($25.23–$27.45, $0.93M total) across 5 trades over 2026-10-30 to 2026-11-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is the first public report of this transaction, making it a primary source of new information.
Market read
A senior executive's $0.93 M stock sale may prompt short‑term downside sentiment, but overall market impact is limited.
What to watch
Potential upcoming data releases or clinical milestones that may offset any short‑term pressure.
Background
Form 4 filings are mandatory disclosures of insider transactions, providing transparency on insider activity.
Ticker impact
President and COO Julie Rubinstein sold 35,643 shares of Adaptive Biotechnologies for $928,891 via a 10b5‑1 plan, disclosed in a Form 4 filing.
likely pressure as the market prices in the insider sell
A senior officer sold nearly $1 M of stock, indicating possible personal liquidity need or reduced confidence, which typically triggers short‑term downside bias.
Market effects
Minimal; biotech sector not broadly affected by a single insider sale.
None
None
Counterpoint
The sale could be routine liquidity management and not reflect company fundamentals.
Key entities
- companyAdaptive Biotechnologies Corp
Biotech firm focused on immune profiling and diagnostics.
- personJulie Rubinstein
President and COO of Adaptive Biotechnologies.



